The litigation centers on allegations that Fractyl Health misled shareholders regarding the effectiveness of its Revita treatment. According to the complaint, the company failed to disclose that Revita performed below expectations and that operational failures at clinical sites for the REMAIN-1 Midpoint Cohort compromised the integrity of reported efficacy data. These omissions allegedly led to an overstatement of the company’s commercial prospects and the clinical validity of its study results.

Shareholders who held GUTS stock during the specified period and suffered financial harm may contact Howard G. Smith at 215-638-4847 or via the firm's website. Participation in the lawsuit as a lead plaintiff is voluntary, and investors retain the right to select their own counsel or remain as passive class members without taking immediate action.